Implication of transcriptional repression in compound C-induced apoptosis in cancer cells

Area of Science:

• Molecular Biology
• Cancer Research
• Pharmacology

Background:

• Compound C inhibits AMP-activated protein kinase (AMPK).
• Previous studies suggest Compound C induces apoptosis, but mechanisms are unclear.
• Cancer cells exhibit resistance to apoptosis, necessitating novel therapeutic strategies.

Purpose of the Study:

• To elucidate the molecular mechanisms underlying Compound C-induced apoptosis.
• To investigate the role of p53 and eukaryotic initiation factor-alpha (eIF2α) in Compound C's effects.
• To evaluate the anticancer potential of Compound C in vitro and in vivo.

Main Methods:

• DNA microarray analysis to assess gene expression changes.
• Western blotting to detect protein levels of p53, Bcl-2, Bcl-xl, and phosphorylated eIF2α.
• Cell viability assays to confirm apoptosis induction.
• In vivo studies to assess anticancer activity.

Main Results:

• Compound C downregulated gene expression and induced p53 protein levels, indicating transcriptional stress.
• Apoptosis was induced in an AMPK-independent manner, similar to known transcription inhibitors like DRB and actinomycin D.
• Compound C treatment led to decreased Bcl-2 and Bcl-xl protein levels and induced eIF2α phosphorylation at Ser51.
• Compound C demonstrated potent anticancer activity in vivo.

Conclusions:

• Compound C induces cancer cell apoptosis through transcriptional repression, p53 induction, and eIF2α phosphorylation.
• Phosphorylation of eIF2α may serve as a novel marker for transcriptional inhibition.
• Compound C exhibits significant anticancer potential and warrants further investigation as a therapeutic candidate.